Advising Provepharm Life Solutions on a 120M€ strategic funding

De Pardieu Brocas Maffei has advised Provepharm Life Solutions, a private French pharmaceutical company that finds new applications for well-known molecules, on a €120 million ($142.3M) strategic funding.

Tikehau Capital will provide the funds and joins the group’s pool of banking investors, including Société Générale, BNP Paribas, Banque Populaire Méditerranée, Crédit Agricole Alpes Provence and Bpifrance.

This new investment will enable the group to speed up its internal R&D and external growth projects, in line with its Horizon 2025 strategy.